← BioTransfer GEO Dataset Finder
GEO series

MERTK inhibition for the treatment of tissue fibrosis [RNA-seq]

GSE235623 Mus musculus (mouse) RNA-seq (gene expression) 86 samples Submitted 2024/03/05 Platform GPL24247
At a glance

RNA-seq (gene expression) · mouse · 86 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Mus musculus (mouse)
Samples
86 samples: 21 conditions, mostly with about 4 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic diseaseScience translational medicine · 2024
Summary (written by the submitters)
Fibrosis is a core pathway that drives the progression of multiple chronic diseases for which there is a paucity of safe and effective treatments. In these diseases, transforming growth factor–β (TGF-β)–driven scarring propels disease progression. However, targeting this ubiquitously expressed cytokine is unlikely to yield a viable and safe antifibrotic therapy; thus, identification of alternative mechanisms to inhibit TGF-β signalling is required.
Read the full summary ↓
We identified Mer tyrosine kinase (MERTK) as a TGF-β–inducible nodal effector of fibrosis that is up-regulated with fibrosis in multiple organs in both mice and humans. MERTK also induces TGF-β expression and promotes it’s signalling resulting in a positive feedback loop that promotes fibrosis. Mechanistically, MERTK regulates both canonical and non-canonical TGFβ signalling. Further downstream, MERTK modulates the fibrotic regulatory gene transcription network by regulating chromatin accessibility, RNA polymerase II (pol II) pausing and reprograming the enhancer landscape. Using mouse models of kidney, lung, and liver fibrosis, we demonstrate that this fibrosis-promoting signalling loop can be interrupted by loss of MERTK expression, leading to marked attenuation of fibrosis. Pharmacologic MERTK inhibition reduced fibrosis either when initiated immediately after injury or when initiated after fibrosis is established. Together, this data suggests that MERTK plays a critical role in modulating organ fibrosis, while small-molecule MERTK inhibitors are an attractive target for the treatment of diseases characterized by fibrosis.
Published in
Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease
Pan Z, El Sharkway R, Bayoumi A et al. · Science translational medicine 2024 · PMID 38569018 · doi:10.1126/scitranslmed.adj0133
This dataset
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE235623_RAW.tar (it can run to tens of gigabytes).

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA986572 and SRA study SRP445412. Searching any of these in the dataset finder brings you back here.

Study design
21 conditions, mostly with about 4 replicates each
BILE DUCT LIGATION (BDL)+DMSO ×6 BILE DUCT LIGATION (BDL)+ MERTK INHIBITOR(UNC… ×6 UUO(Unilateral ureter obligation)+ MERTK inh… ×6 BLEOMYCIN+MERTK inhibitor(UNC569) ×6 BLEOMYCIN+ DMSO ×5 UUO Sham WT ×4 UUO Sham KO ×4 UUO WT ×4 +14 more

Supports a between-group comparison across 85 samples.

How we read this: 21 replicated groups read from 86 sample titles; they account for 85 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

+ 46 more — browse all 86 samples with per-sample file links →

Datasets on a similar topic

Search all mouse RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.